Glenmede Trust Co. NA Boosts Stock Position in DaVita Inc. (NYSE:DVA)

Glenmede Trust Co. NA grew its position in shares of DaVita Inc. (NYSE:DVA - Free Report) by 731.6% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 123,269 shares of the company's stock after buying an additional 108,446 shares during the quarter. Glenmede Trust Co. NA owned 0.15% of DaVita worth $20,207,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Assenagon Asset Management S.A. grew its position in DaVita by 29.6% during the second quarter. Assenagon Asset Management S.A. now owns 50,096 shares of the company's stock valued at $6,942,000 after buying an additional 11,454 shares during the period. Comerica Bank increased its stake in shares of DaVita by 41.4% during the 1st quarter. Comerica Bank now owns 34,431 shares of the company's stock worth $4,753,000 after purchasing an additional 10,074 shares during the last quarter. Quest Partners LLC bought a new stake in shares of DaVita in the 3rd quarter worth approximately $669,000. MBB Public Markets I LLC purchased a new position in DaVita in the second quarter valued at approximately $582,000. Finally, Chase Investment Counsel Corp grew its holdings in DaVita by 56.3% during the third quarter. Chase Investment Counsel Corp now owns 33,084 shares of the company's stock valued at $5,423,000 after purchasing an additional 11,912 shares during the period. Hedge funds and other institutional investors own 90.12% of the company's stock.

Analysts Set New Price Targets

DVA has been the topic of several research reports. Truist Financial boosted their target price on DaVita from $165.00 to $175.00 and gave the company a "hold" rating in a research note on Monday, October 7th. Bank of America increased their target price on shares of DaVita from $139.00 to $145.00 and gave the stock an "underperform" rating in a research report on Wednesday, August 7th. Barclays lifted their target price on shares of DaVita from $150.00 to $164.00 and gave the stock an "equal weight" rating in a research note on Thursday, October 31st. Finally, UBS Group raised their price objective on shares of DaVita from $169.00 to $175.00 and gave the stock a "buy" rating in a report on Thursday, August 8th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $161.80.

Insider Activity at DaVita

In related news, CEO Javier Rodriguez sold 50,000 shares of the firm's stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $165.05, for a total value of $8,252,500.00. Following the sale, the chief executive officer now directly owns 837,835 shares of the company's stock, valued at $138,284,666.75. This trade represents a 5.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 2.00% of the stock is owned by corporate insiders.

DaVita Price Performance

Shares of DVA traded down $2.33 during midday trading on Thursday, hitting $165.63. 558,560 shares of the company traded hands, compared to its average volume of 823,271. DaVita Inc. has a one year low of $98.26 and a one year high of $169.51. The firm has a market cap of $13.58 billion, a P/E ratio of 17.87, a PEG ratio of 0.94 and a beta of 0.89. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33. The stock has a 50-day moving average of $158.47 and a 200-day moving average of $148.99.

DaVita (NYSE:DVA - Get Free Report) last posted its earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share for the quarter, missing analysts' consensus estimates of $2.76 by ($0.17). The firm had revenue of $3.26 billion for the quarter, compared to the consensus estimate of $3.25 billion. DaVita had a return on equity of 88.18% and a net margin of 6.53%. The business's revenue was up 4.6% on a year-over-year basis. During the same period last year, the company posted $2.85 EPS. As a group, sell-side analysts predict that DaVita Inc. will post 9.71 EPS for the current fiscal year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.